A Stock Agilent Technologies, Inc.
US · NYSELast in our picks 2026-10-20 — not in the current list; analysis below is from that screen
Laboratory recovery and resilient consumables demand support a favorable cyclical rebound.
Future value: $181.05 (+6.56%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Bank of America and Barclays maintained Buy ratings.
- ▸Above 50-day MA (+6.61%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (89% of range) — strength
Is A a buy right now?
Trend: A is trading above the 50-day average (+7.22%), RSI 37 — neutral momentum, with a 3-month return of +25.51%.
Valuation & quality: Agilent Technologies, Inc. trades on a trailing P/E of 34.7, forward P/E 26.1, PEG 1.43, price-to-book 6.74; fundamentals show net margin 19.5%, return on equity 21.0%, revenue growth 8.1% year on year.
Analyst consensus: 20 analysts have a mean 12-month price target of $182.05 (+3.5% vs the last close; range $155.00 – $200.00), consensus rating “buy”.
Income: trailing dividend yield 0.59%.
Our screen: STRONG BUY (score 4) — Laboratory recovery and resilient consumables demand support a favorable cyclical rebound.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -6.10% | +1.40% | +17.30% | -2.00% | +4.20% | +11.00% | +12.20% | +0.40% |
Fundamentals
Analyst price target
Technical signals
About Agilent Technologies, Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
Sector: Healthcare · Industry: Diagnostics & Research · United States · 18,200 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.